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Background: This is an observational study undertaken in aim to evaluate the association 
between metabolic syndrome (MS) and high homocysteinemia (HHcy) in relation with cardio-
vascular disease (CVD).
Methods: The study involved 126 subjects with angiographically documented CVD and 65 
healthy subjects. MS has been diagnosed according to the ATP III criteria and plasma homo-
cysteine concentration has been evaluated.
Results: In patients with CVD the prevalence of MS and HHcy is 17.4% and 25.4% respec-
tively; MS coexists with HHcy in 67.2% of patients; analogous results can be observed among 
men and women. HHcy and MS are associated with CVD (OR 2.53, 95% CI 1.95–12.43 and 
OR 5.74, 95% CI 2.67–12.34 respectively) but the presence of the two conditions gives rise to 
a stronger increase in CVD risk (OR 13.11, 95% CI 5.27–32.06).
Conclusions: Our data suggest that HHcy and MS could work together in increasing CVD risk.
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Introduction
The metabolic syndrome (MS) is characterized by obesity, insulin resistance, hyper-
lipidemia, and hypertension. The mechanisms causing MS are poorly understood, 
but insulin resistance is thought to be the major cause (Cranford 2003). Although 
most people with MS have insulin resistance, which confers increased risk for type 2 
diabetes, the primary clinical outcome of this syndrome has viewed as cardiovascular 
diseases (CVD) (Ninomiya et al 2004). Homocysteine is a sulfur-containing amino acid 
formed during the metabolism of methionine. In recent years, hyperhomocysteinemia 
(HHcy) has emerged as an independent and graded risk factor for the development 
of CVD and it seems that HHcy may specially increase the risk when present with 
other risk factors for CVD (Virtanen et al 2005). Although HHcy and MS are both 
associated with CVD, the association between fasting homocysteine levels and MS in 
CVD patients is not well characterized. This is an observational study undertaken in 
aim to evaluate the possible association between MS and high homocysteine plasma 
levels in regard to the risk for CVD.
Subjects and methods
Table 1 shows study subjects characteristics divided in cases and controls; the study 
involved 126 subjects with angiographically documented CVD, 60 men (age: 34–72 
years) and 66 women (age: 36–70 years); angiograms of CAD patients showed at least 
50% stenosis of 1, 2, or 3 coronary arteries. 65 aged-matched healthy control subjects 
were recruited; all were in good general health, had not risk factors for CVD such as 
smoking, high blood pressure or high cholesterol and triglycerid plasma levels. Patients Therapeutics and Clinical Risk Management 2007:3(6) 1000
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affected by type 2 diabetes or smokers were excluded by the 
study, all were in good general health and not taking lipid-
lowering drugs or vitamin B12 and folate supplementation.
MS deﬁ  nition
We applied the condition-speciﬁ  c cut points for the MS from 
the recent NCEP-ATP III report (Executive Summary of the 
Third Report of the National Cholesterol Education Program 
(NCEP) expert Panel on Detection, Evaluation and Treatment 
of High Blood Cholesterol in Adults (ATP III) 2001). The 
ﬁ  ve component conditions are: fasting glucose  100 mg/dL, 
systolic blood pressure  130 mmHg or diastolic blood 
pressure  85 mmHg, triglycerides  150 mg/dL, 
HDL-C 40 mg/dL in men or 50 mg/dL in women and 
abdominal obesity deﬁ  ned by waist circumference 102 cm 
in men or 88 cm in women.
Laboratory methods
In aim to determinate fasting plasma levels of homocys-
teine, triglycerids, LDL-cholesterol, HDL-cholesterol and 
glucose, all the blood samples were drawn from the cubital 
vein between 8.00 a.m. and 9.00 a.m. and stored at −20 °C 
up to the analysis. Triglycerids, LDL-cholesterol, HDL-
cholesterol and glucose concentrations were determined 
by enzymatic-colorimetric methods using standard kits 
(SENTINEL diagnostics) and ﬁ  nally the colored-derivatives 
are photometrically quantiﬁ  ed by spectrophotometer. Homo-
cysteine concentration was measured immunochemically by 
automatic analyzer for biological ﬂ  uid assay (IMX System, 
Abbott S.p.A., Roma, Italy) FPIA (Fluorescence Polariza-
tion Immuno Assay). HHcy was deﬁ  ned as a fasting plasma 
homocysteine 15 µmol/L (Malinow et al 1999).
Statistical analysis
Continuous variables are presented as mean values ± standard 
deviation (SD). Odds ratio and 95% conﬁ  dence interval (CI) 
were used to study the association between HHcy, MS and 
CVD, adjusted for age, sex, LDL cholesterol and smoking 
habit. Findings were considered statistical signiﬁ  cant if 
p value was 0.05. Statistical evaluation of the data was 
performed using standard statistical software (GraphPad 
Prism).
Results
22 subjects (17.4%) among cases present HHcy and 32 
(25.4%) have MS; MS coexists with HHcy in 72 patients 
(67.2%) and analogous results can be observed among men 
and women with CVD. The increase in prevalence observed 
in the MS + HHcy group in comparison with MS and HHcy 
groups is statistically signiﬁ  cant (p  0.001). As already 
known, HHcy and MS are both associated with CVD (OR 
2.53, 95% CI 1.95–12.43 and OR 5.74, 95% CI 2.67–12.34 
respectively); according with prevalence data, when HHcy 
is associated with MS the OR for CVD rises to 13.11 (95% 
CI 5.27–32.06). This result suggests that HHcy is a stronger 
predictor of CVD when present with MS.
Discussion
In the current study, most of cardiopathic subjects (67.2%) 
show both MS and HHcy, whereas subjects with high plasma 
homocysteine levels but without MS are 25.4% and only 
17.4% of the patients present MS with normal plasma homo-
cysteine levels. These data suggest that HHcy may partici-
pate to the metabolic impairment typically observed in MS. 
Therefore, our results conﬁ  rm the well known association 
between HHcy and CVD (OR 2.53, 95% CI 1.95–12.43), so 
they indicate the usefulness of including fasting homocyste-
ine determination in the diagnostic panels of CVD patients 
in order to obtain a better assessment of their cardiovascular 
risk proﬁ  le. In addition, the present study suggests that HHcy 
and MS work together in increasing CVD risk, more than the 
two entities can do alone (OR 13.11, 95% CI 5.27–32.06). 
These ﬁ  ndings surely advice the need to develop strategies 
for controlling the MS and its component conditions as well 
as homocysteine plasma levels. The water-soluble B vitamins 
(especially folate and cobalamin) have been shown to lower 
HHcy (Lonn et al 2006), but their role in reducing CVD risk 
is debated (Bonaa et al 2006; Siragusa et al 2007); actually, 
it seems that vitamin supplementation reduces homocysteine 
plasma levels but it has no effect on the risk of death from 
cardiovascular causes. These ﬁ  ndings suggest that HHcy 
Table 1 Study subject characteristics
 Cases  Controls
 (n  = 126)  (n = 65)
Waist circumference (cm)
 Men  109,6  ± 9,8  101,6 ± 8,9
 Women  95,2  ± 9,6  88,5 ± 7,4
Triglycerides (mg/dL)  194,3 ± 55,4  147 ± 32,9
HDL-Cholesterol (mg/dL)
 Men  39,6  ± 8,3  43,7 ± 7,4
 Women  42,2  ± 9,6  51,2 ± 12,1
Diastolic pressure (mm Hg)  91,1 ± 12,7  79,7 ± 9,2
Sistolic pressure (mm Hg)  140,2 ± 15,8  122,4 ± 10,3
Fasting glucose (mg/dL)  109,7 ± 11,2  99,6 ± 27,1
Homocysteine (µmol/L) 28,4  ± 3,9*  10,15 ± 1,9
Values are expressed as mean value ± standard deviation.
*p  0.05 in comparison with controls.Therapeutics and Clinical Risk Management 2007:3(6) 1001
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needs some other metabolic impairment, such as metabolic 
syndrome, to exert its negative effect on cardiovascular risk 
proﬁ  le. However, Hajer et al (2007) have recently demon-
strated in a large prospective study that the contribution 
of HHcy to SM in determining cardiovascular risk is only 
modest and the deleterious effect of HHcy is greater when 
it is alone than associated with MS.
There is full agreement that therapeutic lifestyle change, 
with emphasis on weight reduction, constitutes ﬁ  rst-line 
therapy for MS. Recently, it has been demonstrated that 
physical activity is an independent life-style habit associ-
ated with a lower homocysteinemia in an elderly population 
(Danker et al 2004). In conclusion, our study reafﬁ  rms the 
clinical importance of the HHcy especially in association 
with MS as signiﬁ  cant risk factors for CVD and the need to 
develop strategies for controlling this syndrome.
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